BURLINGTON, Mass. & NEW YORK - Butterfly Network, Inc. (NYSE: NYSE:BFLY), a company specializing in portable ultrasound technology, anticipates surpassing its 2023 revenue and adjusted EBITDA guidance, as stated during their presentation at the 42nd Annual J.P. Morgan Healthcare Conference earlier this week.
The company's expected revenue for the full year 2023 is projected to exceed the previously issued guidance of at least $64 million, with an improved adjusted EBITDA loss between $75 million and $70 million. This positive outlook is attributed to the company's focus and energy in all business phases, according to Butterfly Network's President, CEO, and Chairman, Joseph DeVivo.
In a recent development, Butterfly Network received FDA clearance for its third-generation handheld point-of-care ultrasound system, Butterfly iQ3. The Butterfly iQ3 is expected to launch within the first quarter of 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.